354 related articles for article (PubMed ID: 23413101)
1. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ
AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
4. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
5. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
[TBL] [Abstract][Full Text] [Related]
6. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
7. Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma.
Zhu R; Wang X; Anderson E; Deng M; Pivirotto S; Jin J; Kassir N; Owen R
AAPS J; 2023 Jun; 25(4):56. PubMed ID: 37266853
[TBL] [Abstract][Full Text] [Related]
8. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
9. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
11. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.
Lowe PJ; Georgiou P; Canvin J
Regul Toxicol Pharmacol; 2015 Feb; 71(1):68-77. PubMed ID: 25497995
[TBL] [Abstract][Full Text] [Related]
12. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
Massanari M; Kianifard F; Zeldin RK; Geba GP
Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
[TBL] [Abstract][Full Text] [Related]
14. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
15. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
[TBL] [Abstract][Full Text] [Related]
16. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
[TBL] [Abstract][Full Text] [Related]
18. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
